ISAL 2019 | Checkpoint inhibitor combination approaches for AML/MDS: an update

Naval Daver

Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives us an update on promising checkpoint inhibitor combination approaches for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video